The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia

[1]  C. Bloomfield,et al.  Intronic miR-3151 Within BAALC Drives Leukemogenesis by Deregulating the TP53 Pathway , 2014, Science Signaling.

[2]  J. Esteve,et al.  MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia , 2014, Leukemia.

[3]  Guido Marcucci,et al.  Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Esteve,et al.  Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene , 2013, Leukemia.

[5]  S. Fröhling,et al.  Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance , 2013, Leukemia.

[6]  A. Kohlmann,et al.  A novel hierarchical prognostic model of AML solely based on molecular mutations. , 2012, Blood.

[7]  M. Caligiuri,et al.  miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. , 2012, Blood.

[8]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[9]  M. D. Boer,et al.  Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia , 2011, Leukemia.

[10]  Guido Marcucci,et al.  The prognostic and functional role of microRNAs in acute myeloid leukemia. , 2011, Blood.

[11]  M. Caligiuri,et al.  Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[13]  N. Hayward,et al.  Characterization of the Melanoma miRNAome by Deep Sequencing , 2010, PloS one.

[14]  J. Rowley,et al.  Leukaemogenesis: more than mutant genes , 2010, Nature Reviews Cancer.

[15]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[16]  C. Bloomfield,et al.  MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. , 2009, Blood.

[17]  Carlos Agustí,et al.  MicroRNAs Expressed during Lung Cancer Development Are Expressed in Human Pseudoglandular Lung Embryogenesis , 2009, Oncology.

[18]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[19]  Christian Langer,et al.  Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Golub,et al.  Distinct microRNA expression profiles in acute myeloid leukemia with common translocations , 2008, Proceedings of the National Academy of Sciences.

[21]  C. Bloomfield,et al.  High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. , 2008, Blood.

[22]  Bob Löwenberg,et al.  MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. , 2008, Blood.

[23]  Jean-Baptiste Cazier,et al.  Distinctive Patterns of MicroRNA Expression Associated with Karyotype in Acute Myeloid Leukaemia , 2008, PloS one.

[24]  M. Caligiuri,et al.  MicroRNA expression in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[25]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[26]  Torsten Haferlach,et al.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin , 2008, Proceedings of the National Academy of Sciences.

[27]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[28]  J. Cayuela,et al.  Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. , 2005, Blood.

[29]  S. Fröhling,et al.  CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[31]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[32]  Acknowledgements , 1992, Experimental Gerontology.

[33]  L. Bullinger,et al.  The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML , 2013, Leukemia.

[34]  M. D. Boer,et al.  MicroRNAs in acute leukemia: from biological players to clinical contributors , 2012, Leukemia.

[35]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[36]  S. Parlee,et al.  This Work Is Licensed under a Creative Commons Attribution-noncommercial 4.0 International License , 2022 .